Solid Tumors, Adult Clinical Trial
Official title:
A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase Ⅰ Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.
This study is a multi-regional, open-label, multiple-dose administration dose-escalation and dose-expansion study, including a Dose-Escalation Phase (Ia) and a Dose-Expansion Phase (Ib). HF158K1 contains multiple copies of the targeting antibody on liposome surface. It is designed to bind and deliver the chemotherapeutic doxorubicin to tumor cells at even very low HER2 expression levels. The study recruits patients with unresectable or metastatic advanced solid tumors (HER-2 positive (IHC 3+, or IHC 2+ with ISH +) or HER-2 low expression (IHC 2+ with ISH -, or IHC 1+)) who have failed or are intolerant (disease progression, or intolerance to chemotherapy, targeted therapy, etc.) to standard treatment, or currently have no available treatment regimen. Phase 1a(Dose escalation) will assess the safety,tolerability,pharmacokinetics of HF158K1 in participants to determine the maximum tolerated dose (MTD) of HF158K1 through the incidence of dose-limiting toxicity (DLT). Phase 1b(Dose expansion) will assess safety and preliminary efficacy of HF158K1 in participants with specific tumor types in selected dose groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06404528 -
Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours
|
N/A | |
Terminated |
NCT04467853 -
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT05698888 -
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04587479 -
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
Recruiting |
NCT05354323 -
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05430373 -
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04739293 -
Study of ON 123300 in Patients With Advanced Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05747339 -
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
|
N/A | |
Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05228015 -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05018273 -
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04621435 -
Imaging of Solid Tumors Using FAP-2286
|
Phase 1 | |
Recruiting |
NCT06088472 -
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05768139 -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 |